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BACKGROUND: One way to overcome the genetic and molecular variations within glioblastoma is to treat each
tumour on an individual basis. To facilitate this, we have developed a microfluidic culture paradigm that maintains
human glioblastoma tissue ex vivo. METHODS: The assembled device, fabricated using a photolithographic process,
is composed of two layers of glass bonded together to contain a tissue chamber and a network of microchannels
that allow continued tissue perfusion. RESULTS: A total of 128 tissue biopsies (from 33 patients) were maintained in
microfluidic devices for an average of 72 hours. Tissue viability (measured with Annexin V and propidium iodide)
was 61.1% in tissue maintained on chip compared with 68.9% for fresh tissue analysed at commencement of the
experiments. Other biomarkers, including lactate dehydrogenase absorbance and trypan blue exclusion,
supported the viability of the tissue maintained on chip. Histological appearances remained unchanged during
the tissue maintenance period, and immunohistochemical analysis of Ki67 and caspase 3 showed no significant
differences when compared with fresh tissues. A trend showed that tumours associated with poorer outcomes
(recurrent tumours and Isocitrate Dehydrogenase - IDH wildtype) displayed higher viability on chip than tumours
linked with improved outcomes (low-grade gliomas, IDH mutants and primary tumours). conclusions: This work has
demonstrated for the first time that human glioblastoma tissue can be successfully maintained within a
microfluidic device and has the potential to be developed as a new platform for studying the biology of brain
tumours, with the long-term aim of replacing current preclinical GBM models and facilitating personalised
treatments.
Translational Oncology (2020) 13, 1–10Introduction
Gliomas make up 81% [1] of brain tumours, and of all gliomas,
glioblastoma (GBM) represents nearly half (47%) [2] of all cases. The
World Health Organization (WHO) classification of tumors of thecentral nervous system uses histological and genetic markers to
identify 5 forms of GBM [3]. The Cancer Genome Atlas group used
genetic fingerprinting studies, patient demographics and survival data
to identify 4 clinically relevant subtypes [4]. These classification
methods are not mutually exclusive and are increasingly combined to
characterise an array of genetically and phenotypically different types
of GBM. Multiple forms exist, but regardless of subtype, the
diagnosis of a GBM is a devastating one with a poor prognosis, which
has remained essentially unchanged in over 90 years. Stupp et al. [5]
showed the addition of temozolomide (TMZ) to radiotherapy and
surgery increased survival by 2.5 months compared with surgery and
radiotherapy alone. Despite this survival benefit, the nature of the
disease, which sees widespread permeation of tumour cells along
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eventually fail. Median survival ranges from 9 to 15 months [6,7].
Undeterred by decades of research and treatments, GBM kills 97.3%
of patients within 5 years of diagnosis [8]. While addressing tumour
stem cells and treatment resistance in GBM, potential cures must
resolve the complex issue of tumour heterogeneity, optimising
treatment based on the individual tumour type.
Current strategies aimed at developing new treatments for GBM
are encumbered with an imperfect process of drug screening as well as
the absence of a good model of the disease. Cell cultures, currently the
mainstay of preclinical assays, do not recapitulate the infiltrative
nature of the tumour and possess significant molecular and
pathological differences from human gliomas [9]. Mouse models
[10] and patient-derived xenografts (PDXs) [11] provide a solution to
this particular issue but are costly and time-consuming, making these
models only suitable in drug-development testing, with no scope to
apply them to a personalised approach.
A more ideal treatment paradigm involves being able to study
patient tumours in the laboratorydfreshly biopsied at the time of
surgical debulking and kept in a viable state long enough to analyse
response to various treatment modalitiesdand offering treatment to
patients based on specific results. Just as microbiologists rationalise
treatments based on culture and sensitivity, an approach that allows
analysis of human GBM tissue ex vivo could personalise treatment
and improve patient outcomes.
Microfluidics (MF) is a fast-growing area of research that allows
experimentation with mimicry of natural conditions. Fluid flow
through microdevices takes place at a submillilitre scale, with Reynold
numbers less than 100 [12], where viscous as opposed to inertial forces
dictate flow. The resultant laminar flow means diffusion becomes the
predominant form of molecular interactions, as is seen in cells and
tissues. MF devices have been used to explore a wide range of biological
processes, with devices created to mimic complex organs [13] or
facilitate molecular tests [14]. More recently, devices that maintain
whole tissues ex vivo for 3e7 days have been created, allowing
chemotherapy and radiotherapy testing and correlating response to in
vivo tumour behaviour [15e19]. As a preclinical model, such a system
would effectively mimic the native tumour microenvironment while
avoiding prolonged incubation periods required with PDX. As a
clinical model, it would allow testing of individual tumour samples
within a short time frame, potentially allowing key analyses of the
tumour to asses for subtype and response to specific treatment and
allowing stratification of the patients to particular drug sensitivities.
The issue of intratumour heterogeneity can be overcome by real-time
measurements of the net response of the tumour to a single agent or
combination therapy. Such a system introduces the desired degree of
flexibility to deal with an adaptive tumour-like GBM and would
significantly enhance clinical research, aiding scientists and clinicians in
preclinical drug development, patient stratification for drug trials and
predicting responses to treatment in the clinic.
Currently, no such model exists. The development of such a
platform would be instrumental in reducing the mortality associated
with the disease and bring the elusive cure closer to our reach. The
aim of the current research project is to establish a robust MF tissue
culture paradigm for the maintenance of human GBM tissue. Using
an MF device similar to that previously described [20], GBM tissue
biopsies from surgery were successfully maintained within the MF
device, with continued perfusion and withdrawal of medium, over a
3-day period.Material and Methods
Fabricating and Assembling the Chip
The MF device was fabricated using standard photolithography
and wet etching techniques. A photomask containing the layout of
the microchannel network was developed by photoreduction using a
computer-assisted design packagedAutoCAD LT software (Autodesk
Ltd.). The photomask was aligned onto a 30  30-mm crown white
glass, precoated with photoresist. The precoated glass, left in contact
with the photomask, was exposed to ultraviolet radiation for just over
a minute, creating the desired pattern and allowing further
development and etching in 1% (v/v) hydrofluoric acid at 65 C in
a heated ultrasonic bath. The etched glass chip was then cleaned and
thermally bonded with a top layer (with corresponding predrilled
holes) at 600 C for 3 hours. The completed device consisting of the
two glass plates bonded together is represented in Figure 1. The
thinner bottom (1 mm) layer has a network of microchannels of
190-mm width and 70-mm depth, which diverge into exit
microchannels.
Further modifications of the basic unit were required: a
semipermeable barrier (circular mesh) was secured onto the bottom
of the tissue cavity, followed by sealing a PEEK microport (Anachem)
to the surface of the top glass layer such that the circular tissue cavity
could be enclosed using an English-threaded adapter (Anachem). The
adapter contained a hollow central portion that was filled with
Polydimethylsiloxane (PDMS - Dow Corning) to allow gaseous
exchange into the tissue compartment. The fabricated device was
finalised by connecting 0.8-mm (internal diameter) by 1.58-mm
(external diameter) ethylene tetrafluoroethylene Teflon tubing
(Anachem) to the inlet and outlet channels with epoxy adhesive and
a graphite ferrule. For these experiments, only one inlet and one
outlet channel were required. The completed device was sterilised
with 70% (v/v) ethanol/distilled water before use.
Recruitment
The study received ethics approval from the Yorkshire and the
Humber - Humber Bridge research ethics comittee (13/YH/0238)
and Hull and East Yorkshire NHS Trust (R1584). Case notes, clinical
imaging, and multidisciplinary team outcome plans for potential
participants admitted to the recruiting hospital were reviewed, to
identify cases where a GBM tumour was suspected.
Inclusion Criteria
Patients aged >18 years undergoing a diagnostic procedure or
planned tumour resection where a sample of brain tumour tissue was
expected to be taken, with a principal diagnosis of GBM, were
included.
Exclusion Criteria
Participants lacking capacity to give informed consent were
excluded.
Experimental SetUp
At operation, the most cellular portion (i.e., avoiding necrotic
tissue) was acquired and immediately placed in a 50-ml polypropy-
lene tube containing the maintenance media (Table 1). Samples were
sectioned within 60 min of collection into 10- to 15-mg pieces,
approximately 2 2 2 mm, and placed into the central chamber of
the MF device, sealed with the microport adaptor. The tumour chip
Figure 1. Experimental setup. (A) Inlet and outlet (access) channels as well as a central channel were drilled into the top glass layer.
Channel networks were etched into the bottom layer, producing channels 190 μm in width and 70 μm in depth. The tissue chamber
was sealed with a microport and PDMS-filled adaptor. The tissue chamber has a volume of approximately 20 μL. Adapted from
Hattersley et al [34]. (B) Pictures of the chip. Note: Two outlet holes glued with glass coverslip. (C) A picture of the assembled
microfluidic chip. (D) Schematic of microfluidic setup (Adapted fromDawson et al.) [60]. (E) The device with GBM tissue, connected
to syringes and syringe pump.
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the appropriate media and attached to a calibrated PhD 2000 Syringe
Pump (Harvard) within a Perspex box with a thermostat regulated
temperature of 37C. Medium was infused into the chip and tissue at
a rate of 4 mL min1 (Figure 1E). In conjunction with tissue
maintained within the MF device, a sample of the fresh GBM tissue
was prepared for baseline histology and immunochemistry; additional
tissue biopsies were enzymatically disaggregated, in preparation for
flow cytometry studies.
The tissue on chip was perfused continuously for 72 hours, and the
effluent samples were collected every 2 hours during the day and
overnight samples were collected over a range of 12e18 hours.
Infusions were stopped after 72 hours, and tissue samples were
removed from the device for post-chip analyses.
Chip Analysis
Samples removed from the MF device underwent a number of
different analyses.
Histological Preparations
Haematoxylin and eosin (H&E) staining and immunohistochem-
istry (IHC) were performed for tissue processed after tissueTable 1. Composition of the Culture Media Used in the Microfluidic Experiments
Culture Medium
Dulbecco's Modified Eagle Medium, fortified with 4.5 g/L of glucose
Foetal bovine serum, 10% (v/v) heat inactivated
Penicillin (0.1 U/ml)/streptomycin (0.1 g/ml) mixture
Sodium pyruvate (5 mM)
HEPES (25 mM)maintenance in the MF device as well as those obtained fresh from
the patient. Tissues were initially placed in 1.5 ml of 4%
paraformaldehyde and processed for paraffin embedding. Wax-em-
bedded tissues were cut (5 mm) and stained with H&E. IHC was
performed using the Leica Bond III automated immunostaining
platform (Leica) in conjunction with the Leica Bond Polymer Refine
DAB detection kit (Leica), as per the manufacturer's guidelines. Ki67
and Caspase 3 proteins were targeted with the respective antibodies,
MIB1 and ASP175. All H&E and IHC slides were viewed using an
Eclipse 80i microscope (Nikon), and digital images were acquired
using an Infinity 3 Microscope Camera (Roper Technologies) along
with Image Pro Premier Software (Media Cybernetics). Digital images
of the IHC slides were analysed using ImmunoRatio, a free
Web-based application for automated image analysis of stained tissue
sections [21e23]. Proliferation and apoptotic indices were calculated
as the number of positively stained cells divided by the total number
of cells, multiplied by 100. For each slide, this was performed on 2e3
randomly chosen high-power field images that contained positively
stained cells.Flow Cytometry
Tissue processed for testing was dissociated into single cells by
initially mincing the tissue using a scalpel in a criss-cross cutting
action. The minced tissue was added to a 1-ml tissue disaggregation
solution (Sigma) and kept in an incubator at 37C for 2 hours on a
tube rotator. The filtered disaggregated solution was centrifuged at
400 x g for 5 min and the pellet mixed with 1 ml of HEPES buffer.
Both Annexin V (AV) and propidium iodide (PI) were then added to
500 ml of the cell suspension, allowed to mix for 15 min in the dark,
Table 3. Characteristics of the Tissues Placed in the Microfluidic Devices
GBM Samples No.
Weight 12.1 mg (±2.2)
Nonperfusion time 69 min (range 40e120 min
Length of perfusion 70.2 hours (±6)
Blocked devices 20
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cytometer (BD) to stratify cells according to AV and PI staining. Data
acquisition was performed using the BD CellQuest Pro software
which used the clustering of cell events, into four distinct populations:
cells with minimal to no AV and PI staining (healthy); cells positively
stained for AV but with the cell membrane still intact, hence
excluding PI (early apoptosis); cells that have undergone irreversible
apoptotic changes that mean the cell membrane has lost its integrity
and is permeable to PI (late apoptosis); and finally, cells that have not
gone through the apoptotic pathway and died via necrosis (only
positive for PI, necrotic).
Trypan Blue Staining and Cell Counts
The disaggregated tissue cell suspension (10 ml) was mixed with
10 ml of 0.4% trypan blue solution. The mixture was pipetted onto a
haemocytometer, and the viable percentage was calculated by dividing
the number of viable cells (cells that excluded the dye/unstained) by the
total number of cells (stained and unstained) multiplied by 100 [24].
Lactate dehydrogenase Analysis
Cell viability was also assessed using a colorimetric cytotoxic assay,
lactate dehydrogenase (LDH) Cytotoxic Kit (Sigma Aldrich). The
LDH assay was used as per manufacturer's protocol on the effluent
collected from the MF device to quantify LDH release via absorption
using the colorimetric assay using the Synergy HT Plate Reader
(BioTek) at 490 nm.
Statistical Analysis
Statistical analysis was carried out using Graph Pad Prism (Graph
Pad Software). A combination of paired and unpaired t-tests was used
to determine statistical significance between fresh tissue assays and
assays within the MF device. A P value of0.05 was considered to be
significant, and thus, the null hypothesis that the differences in the
results were due to chance was rejected. All graph error bars display
the standard error of the mean.
Results
A total of 128 human GBM tumour specimens (from 33 patients)
were obtained for tissue maintenance within a MF device (Table 2).
Tissues maintained within the device were cultured for an average of
70.2 hours (±6). The nonperfusion time (length of time from sample
acquisition to perfusing the tissue within the MF device) was 69 minTable 2. Histological Types and Demographics of Patients Included in the Study
Patients Recruited (n ¼ 33) No.
Age 59.2
Sex (M:F) 2.3:1
WHO Grade Tumour
GBM IDH1 Wild Type 23
GBM IDH Status Unknown 1
Gliosarcoma 1
Anaplastic/GBM IDH1 mutant 3
Anaplastic oligoastrocytoma IDH1 mutant* 1
Schwannoma Grade 1* 1
Anaplastic astrocytoma IDH1 wild type* 2
Gemistocytic astrocytoma IDH1 mutant* 1
Primary tumours 29
Recurrent tumours 4
Surgical Resection
Debulking 31
Biopsy 2
* Non-GBM tumours.)(range of 40e120 min) (Table 3), with no correlation between the
nonperfused time and viability of samples, when analysed (n ¼ 28)
using Pearson's correlation coefficient, r2 value of 0.027 and P value
of 0.41. After the tissue maintenance period ended, samples were
removed from the device, and the tissues and effluent were analysed.
Tumour MorphologyOn inspection of the tissues at the end of experimentation, there
was little difference in the macroscopic appearance of the tumour
samples when compared with tissue samples resected before the
commencement of the experiment. Tissue maintained within the MF
device for 72 hours did not disrupt the tissue architecture when H&E
sections were compared with fresh tissue samples (Figure 2).
Characteristic features of GBM, including pleomorphic nuclei,
vascular proliferation, pseudopalisading, and areas of necrosis were
equally visible in both tissue samples maintained on chip, as well as
those processed immediately after sample acquisition. In particular,
there were no differences in cellular density and architecture within
peripheral portions of the tissue sections compared with the central
portions.
Immunohistochemistry
Similarly, immunohistochemical markers were relatively well
preserved in tissue within the chip over the 72-hours period when
compared with fresh tissue (Figure 2). The average proliferation index
(Ki67 staining) among 14 matched pairs (fresh and chip tissue) was
16.6% (±15.5) for fresh tissue compared with 15.9% (±17.7) for
tissue maintained on chip (P¼ 0.74). Caspase 3 staining of tissue (13
matched pairs) did not show any significant difference between fresh
tissue and chip tissue with an average apoptotic index of 38.9%
(±23.9) and 44.4% (±21.3), respectively (Figure 3).
AV and PI
AV is a protein with a high affinity for translocated phosphati-
dylserine in the outer membrane of cells, which occurs during
apoptosis [25]. The measurement of AV is coupled with a dye
exclusion testdPI, intercalates with DNA, is unable to cross through
intact cell membranes, making it a valuable stain for identifying
necrotic cells, as well as those at the end stages of apoptosis. While AV
staining only occurs in apoptotic cells, PI staining will be seen in any
cell with a disrupted cell membrane. Viability of disassociated cells
procured from lysed tissue sections was analysed using flow
cytometric AV and PI assays. Estimates of tissue viability, as well as
measures of apoptosis and necrosis, were calculated (Figure 4A).
Mean viability of fresh tissue controls was 68.9% (±29.8) compared
with 61.1% (±28.3) of tissue maintained on chip. Despite a mean
difference of less than 8%, the difference was statistically significant
when analysed with a paired t-test, P ¼ 0.01 (Figure 4C). Stratifying
results according to histological diagnosis showed that GBM tissue
viability (n¼ 27) was greater than lower grade tumours (n¼ 5), with
Figure 2. Representative images of Ki67 IHC (n¼ 14) (A, fresh tissue; B, chip tissue); H&E sections (n¼ 28) (C, fresh tissue; D, chip
tissue); and Caspase 3 IHC (n ¼ 13) (E, fresh tissue; F, chip tissue) of GBM tissue. All images are taken at 400 magnification.
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GBM tissue which had a mean viability of 60.1% (±28.8) P ¼ 0.01.
Trypan Blue
Trypan blue staining of disassociated cells allowed visual
confirmation of cell viability via dye exclusion. This was performed
on the disaggregated cells from fresh tissue controls and chip tissue
(n¼ 19). The results from the 6 matched pair samples revealed mean
cell viability of 73% (±14.2) for fresh tissue and 61% (±26.4) in
tissue that had been maintained within the MF device for 72 hours
(P ¼ 0.16). Trypan blue assays were concordant with AV/PI assays
with strong linear relationship between the two viability assays (r2
value of 0.78).
Analysis of the effluent (LDH Absorbance)
The pattern of LDH release (measured in terms of LDH
absorbance) into the effluent from chip tissue was distinctly similar
in all samples maintained on chip. This is primarily one in which
there is an initial peak in LDH absorbance (thought to be attributed
to tissue dissection) followed by a low and steady state of absorbance
[20]. Figure 5A summarises the average LDH released at set time
points during all experiments and confirms this pattern of LDH
release. The injection of a tissue lysis solution to the tissues on chip atthe end of the maintenance period (performed on 8 GBM samples at
the 71st hour) was associated with an increase in LDH release
(measured by absorbance). Figure 5B displays the LDH absorbance in
the 6th patient, where there was a 4-fold increase in the amount of
LDH released after the introduction of the lysis solution. Analysis of
all the effluent samples collected immediately after introduction of the
lysis solution revealed, on average, a 3-fold increase in LDH.Correlation with Clinical Outcomes
There was no clear congruity between patient outcome and
viability or performance of tumour on chip. However, there was a
disparity in confounding factors known to have an impact on patient
survival, such as age [26], postoperative therapy [5], extent of tumour
resection [27] and number of previous operations [28]. One of the
more sensitive markers of GBM prognosis is the extent of tumour
resection [27,29e33], and it was possible to stratify the performance
of tissue on chip according to the extent of resection. When
evaluating only patients that had greater than 90% of their tumours
resected, there was a trend towards reduced viability in tumours from
patients who survived beyond 250 days (n ¼ 5), compared with
patients who died within 250 days (n ¼ 5). When comparing the
performance of recurrent tumours (n ¼ 4) with that of primary
tumours (n¼ 22), there was a trend towards improved viability (79%
Figure 3. Average proliferation (Ki67) index for fresh tissue
(stained immediately) and chip tissue (stained after 72 hours in
the microfluidic device) n¼ 14 paired tissue samples (P¼ 0.74);
Average apoptotic index (Caspase 3) for fresh tissue (stained
immediately) and chip tissue (stained after 72 hours in the
microfluidic device); n ¼ 13 paired tissue samples (P ¼ 0.14).
6 Microfluidic Maintenance of Human Glioblastoma Olubajo et al. Translational Oncology Vol. 13, No. 1, 2020±15.3 vs. 57.5% ±29.9) as measured with AV/PI flow cytometry.
Similarly, Isocitrate Dehydrogenase (IDH) wild type tumours
retained greater viability on chip than the IDH mutant tumours
(76.7% ±22 vs. 55.7% ±13.4). However, there was no statistically
significant difference when the groups were compared with a t-test
(Figure 6).
Discussion
The present study maintained 128 GBM tissues from 33 patients
within MF devices for 3 days. The bespoke device was made from twoFigure 4. Flow cytometric analysis of matched pairs (fresh tissue a
PI-). (A) Dot plot produced on CellQuest Pro software displaying ho
into four quadrants. (B) Converting the flow cytometric analysis to
tissue vs. chip tissue) to show the fate of disaggregated cells a
cytometer. The proportion of healthy cells (cells with minimal A
compared with 61.1% in tissue maintained in the microfluidic devi
a paired t-test; P ¼ 0.01.layers of glass thermally bonded to incorporate connected micro-
channels and a tissue chamber, facilitating the continuous perfusion
of GBM tissue with nutrient media. Cell viability assays, including
AV and PI flow cytometry, LDH release, trypan blue dye exclusion,
and histological and immunohistochemical analyses confirm that
viable tissue was maintained during the assigned time. Results of
tissue viability and morphological appearances were comparable to
those of fresh tissue that was analysed immediately after excision from
the patient.
The MF device used in the present study has been established in
the maintenance of a variety of tissues including animal liver biopsies
[34], human colorectal cancer specimens [35,36] and head and neck
cancers [20,37,38]. Hattersley et al. kept liver tissue from rats in a
viable state within the device for 70 hours and showed that tissues
retained normal morphology on H&E sections as well as viability,
measured with LDH release and urea and albumin synthesis [39].
The group expanded on the applications of the device by maintaining
head and neck squamous cell carcinomas for 7 days, proving tissue
was viable with LDH and a tetrazolium proliferation assay [20].
Similarly, Bower et al. found that PI and trypan blue staining in head
and neck cancer tissues maintained on chip for 48 hours was
comparable to tissue that was processed immediately from the patient
[37]. Here, for the first time, human GBM tissue biopsies have been
maintained in a MF device. Previous studies focused on maintaining
human GBM tissue, date back to the 1970s, and using static culture
techniques in culture dishes that required the culture media to be
replenished every 1e4 days [40e43]. More recently, a number of
groups have maintained human GBM tissues on collagen gel matrices
[44] and on membrane culture inserts (Millipore) [45,46] but none of
these experimental models have applied continuous tissue flow.
Compared with previous static culture experiments, the length ofnd chip tissue) used to quantify proportion of healthy cells (AV-/
w the flow cytometric analysis of Annexin V and PI is quantified
a Histogram. (C) Histogram of 26 matched pairs of tissue (fresh
fter Annexin V and PI staining and stratification with the flow
nnexin V and PI staining) was 68.9% in Fresh GBM samples
ce. This difference was statistically significant when tested with
Figure 5. Average LDH absorbance from effluent samples collected over the 72-hours time period. (A) Graph displaying the average
absorbance values for each time point from all experiments, e.g., the average absorbance of all effluent samples collected at
2 hours (first value on graph) after the start of the experiments was 0.84 AU. Four hours after the start of the experiments, the
average absorbance from the effluents collected was 0.54 AU. The graph confirms the trend of an initially high LDH absorbance,
followed by a low and stable absorbance value. (B) Representative graph (n¼ 8) displaying LDH absorbance over time in one of the
patient's GBM sample, where there was a 4-fold increase in LDH absorbance after introduction of the lysis solution.
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tissue sections cultured for more than 3 days, one for 5 days and
another for a week. Rubenstein and Herman were able to culture
GBM explants on a sponge foam matrix, changing the culture media
twice a week, for up to 4 months [40,47]. They showed that tissue
architecture and cytological features were conserved over the period;
however, viability, cell death, or apoptosis were not measured norFigure 6. A) Bar graph comparing the viability (determined by Ann
gliomas (n ¼ 5), P ¼ 0.01. (B) Comparing viability (with Annexin V a
(n ¼ 4). Results were not significantly different; P ¼ 0.08 as analy
Annexin V and PI assay) of recurrent tumours (n¼ 4) with that of pri
found (unpaired t-test; P ¼ 0.017).correlated with the histological data. Ono et al. cultured 22 GBM
tissues on collagen gel matrix assays for 7 days and treated the tissues
with a variety of chemotherapeutic agents, and although the group
were able to assess the inhibitory effects of the drugs, they did not
report on the viability of the untreated tissues [44]. Merz et al.
maintained 12 GBM tissues for over 2 weeks and showed that
histological appearances were maintained over that time period;exin V and PI) of GBM (n ¼ 27) tissues on chip with grade 1e3
nd PI assay) of IDH wild type (n ¼ 20) with IDH mutant tumours
sed with unpaired t-test. (C) Comparing viability (measured with
mary tumours (n¼ 22). No statistically significant difference was
8 Microfluidic Maintenance of Human Glioblastoma Olubajo et al. Translational Oncology Vol. 13, No. 1, 2020however, the group did not report on how viability assays of tissue
slice cultures compared to fresh tissue [46]. To our knowledge, the
present study is the largest series of human GBM tumours maintained
as whole tissue pieces as well as represents the first time that the
combined analysis of histology, IHC, and cell viability assays has been
used to gain a comprehensive understanding of the fate of GBM
tissue cultured, ex vivo. It provides an accurate estimate of how well
maintained the tissue is over a 72-hours period and the feasibility of
using the method as a preclinical model for GBM testing.
Earlier iterations of this device had maintained human tissues
successfully with a flow rate of 2 ml per min. Studies on animal brain
slices maintained smaller tissue sections (350- to 500-mm thick)
within a range of flow rates between 0.3 ml and 17 ml per min
[48e51]. The rate of perfusion is specific for each device and is
adjusted to account for the nutrient media used, as well as the tissue
type and thickness. Normal cerebral blood flow is approximately
50 ml per 100 g of tissue per minute, but in GBM, the cerebral blood
flow can range between 39 and 82 ml/100 g/min [52]. This equates
to a rate of 4e8 ml/min per 10 mg of tissue, a rate matched during our
experiments with flow of media at 4 ml per min for GBM tissues of an
average wet weight of 12.1 mg. Benefits of continuous flow of
nutrient media over static brain tissue cultures have been stressed in
previous studies. Reid et al. found failure of electrical activity within
hippocampal brain slices if nutrient flow stopped for over a minute
[53]. Rambani et al. proved that viability of their brain slices was
significantly better if the tissue was perfused at 20 ml per hour
compared with nonperfused tissue slices [49] and recently Killian
et al. were able to show that perfusion of brain tissue correlated with
an improvement in tissue cell viability, as well as the thickness of the
tissue mantle, which thinned significantly with nonperfused tissue
[54]. Optimisation experiments in the present study showed that
tissue maintained with MF flow outperformed static tissue cultures in
terms of cell viability, LDH release, and morphological appearances
(Figure 5). The benefits of tissue flow likely arise from the mimicry of
normal in vivo conditions where there is continuous influx of
nutrients as well as removal of waste products at a constant rate,
recapitulated within a MF culture paradigm.
Strengths of the study include the reliability of the method, with an
inexpensive and efficient model for GBM tissue maintenance.
Compared with other GBM models such as cell spheroids and
PDX, a MF tissue chip can be set up in less than 2 hours of the tissue
being resected. A total of 97% of GBM tissues were successfully
cultured for the duration of the experiments without any disruption
to the continuous inflow of nutrients and removal of waste, all with
minimal hands-on input required once the system had been set up.
Such reliability in a preclinical model can challenge current options
such as PDX, which currently have an engraftment rate that can be as
low as 22% [11] and require several weeks to months to develop
before they can be tested [55].
There was no correlation between tissue viability on chip and
patient survival. Validity of the model requires the performance of the
tissue on chip to have some resemblance to the in vivo behaviour of
the tumour. There remains, however, a complex relationship between
tumour behaviour and survival, with factors including patient age,
performance status, the extent of tumour debulked, and the treatment
provided all having an impact on survival. Patient survival is
determined by the difference between the patient's risk factor profile
(determines degree to which the patient can defend against
deleterious tumour effects) and the inherent tumour biology (aswell as treatment resistance). Patient survival is probably not the best
correlate to tissue viability on chip because survival is so
multifactorial.
Instead, the performance of the tissue on chip can be used to
deduce the inherent tumour behaviour or aggressiveness. When
patient risk factors are controlled for, the performance of the tumour
on chip does bore out some association with patient survival in terms
of viability. Evidence suggests that recurrent GBMs after treatment
display phenotypic transition from proneural to mesenchymal
subtype, leading to disease recurrence and a more aggressive tumour
[56]. In our study, recurrent tumours were the more sustainable and
viable tumours on chip compared with primary tumours. Also, in
keeping with the trend was the finding that GBM tumours had higher
cell viability than grade 1e3 tumours. There was also improved
viability in the IDH wild-type tumours, which generally have a worse
prognosis than IDHmutants [57]. Although these differences did not
reach statistical significance, the trend was commonplace on testing.
Further experiments with a larger cohort are required to clearly
elucidate the associations and clarify the usefulness of the method in
predicting the aggressiveness of GBM tumours.
With such promising results on the assessment of tissue viability of
samples maintained on chip, the response of tissues on chip to drugs is
essential to ensure the model is fit for purpose. Early results are yet to
show any significant effects, but appropriate dosing, delivery
methods, and duration of treatment are yet to be established. Further
work is required to better understand the method and explore the
benefits of different methodological iterations, including the effects of
changing the direction of flow within the chip to one that is
perpendicular, which is known to improve viability by enhancing the
diffusion of nutrients. Also necessary is more intensive testing by
prolonging the length of time the tissue is maintained, which would
support more detailed drug testing, and testing experimental and
established chemotherapeutic drugs such as temozolomide. The effect
of radiotherapy is required to ensure that current treatment standards
can be simulated on GBM tissue on chip. Carr et al. were able to
continue tissue maintenance within their MF device while irradiation
of the tissue on chip took place using a 6-MV photon beam from a
Varian Linear Accelerator [38]. All this will allow a more robust
examination of the MF culture paradigm as a GBM ex vivo model.Conclusion
A diagnosis with glioblastoma equates to a poor prognosis regardless
of treatment. Conventional therapy (surgery, radiotherapy, and
chemotherapy) affords a modest survival benefit of approximately 12
months compared with that of patients who are left untreated [58].
This pilot study is the first time that a MF device has been used to
maintain human GBM tissue ex vivo and is also the largest series of
human GBM tumours "cultured" ex vivo. Although still in its infancy,
the use of MF principles to study whole tissues is improving our
understanding of complex diseases. Analysis of experiments with a
larger number of patients will allow a more definitive exploration of
the method and its potential as a preclinical disease model, a model
with the prospect of enabling more detailed inspections of GBMs,
more accurate predictions of treatment responses, and better
outcomes for patients. GBM treatment starts with maximal safe
resection, and there is, on average, 4e6 weeks between surgical
resection and adjuvant therapy [59]. There is a potential to use this
time to study individual characteristics of a tumour biopsy in a MF
device and to tailor adjuvant therapy based on biological testing.
Translational Oncology Vol. 13, No. 1, 2020 Microfluidic Maintenance of Human Glioblastoma Olubajo et al. 9More enticing is the possibility of a new preclinical drug model for the
investigation of novel therapies to treat GBM.
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